



Editorial

World Tuberculosis Day 2021 Theme – ‘The Clock is Ticking’ – and the world is running out of time to deliver the United Nations General Assembly commitments to End TB due to the COVID-19 pandemic



On March 24th 1882 Koch's announcement in Berlin of the discovery of the microbial cause of tuberculosis (TB), *Mycobacterium tuberculosis*, heralded a major breakthrough, bringing hope for a devastating disease which at that time caused the death of one in seven people in Europe and the Americas. (Wallstedt and Maeurer, 2015). One hundred and twenty years later, and despite the availability of effective treatment for the past 6 decades, 1.4 million people die of TB annually (WHO, 2021a). Over the past 15 months, the unprecedented COVID-19 pandemic has disrupted health services globally (Cilloni et al., 2020) and has negatively impacted on gains being made in global TB control efforts to achieve End TB targets (Sahu et al., 2020; STOP TB, 2019).

The theme of this year's World TB Day March 24th, 2021, ‘**The Clock is Ticking**’ (WHO, 2021b), conveys the sense of urgency that the world is running out of time to deliver the commitments to End TB made by global leaders at the United Nations General Assembly high level meeting on TB (UNGA, 2018). This theme is particularly appropriate and critical in light of the devastating COVID-19 pandemic which is currently the top killer from an infectious disease globally, with TB now being shifted to second place (WHO, 2021a; WHO, 2021c). Since the end of December, 2019, when the WHO was made aware of several cases of atypical pneumonia in Wuhan, China, caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as of March 15th 2021, there have been 119,603,761 confirmed COVID-19 cases, with 2,649,722 deaths, reported to WHO (WHO, 2021c).

In commemoration of World TB Day March 24th, 2021, the International Journal of Infectious Diseases is once again publishing a specific TB Theme issue of 18 articles covering a range of topics.

The October 2020 WHO Global TB report and the United Nations (UN) Secretary-General's 2020 progress report on TB, are reviewed by Chakaya et al. (2021). They reflect on current TB control strategies in light of the United Nations (UN) targets set in the political declaration at the September 2018 UN General Assembly high-level meeting on TB held in New York (UNGA, 2018). Progress in achieving TB control targets has been very slow. Globally, an estimated 10.0 million people developed TB disease in 2019, and there were an estimated 1.2 million TB deaths among HIV-negative people and an additional 208,000 deaths among people living with HIV. In addition, preliminary assessments of how the

unprecedented, devastating COVID-19 pandemic is affecting TB health services, interrupting and slowing down treatment and prevention efforts. It is anticipated that the End TB strategy target of ending TB by 2035 will not be met. The WHO 2020 TB Report (WHO, 2021a) states that a 50% drop in the number of people with TB detected, could result in up to 400,000 additional TB deaths in a year. Innovative plans are needed to maintain all TB services as well as access to these services, in the wake of the COVID-19 pandemic and investments in the development of low-cost rapid diagnostic tests for both COVID-19 and TB are urgently needed. There needs to be a rejuvenated, sustained, and concerted effort to identify and treat ‘missing people with TB’. Governments of high TB incidence countries need to ensure there are rapid TB diagnostic services available in every health facility, so all TB cases can be reached. Global health inequities that underlie differences in TB disease burden, as well as daunting environmental health challenges, need to be addressed by multiple approaches and sectors.

Fox et al. (2021) highlight that latent tuberculosis infection affects one quarter of the world's population and that despite effective oral treatment regimens being available, scale-up and rollout of TB preventive treatment (TPT) remains limited. They describe strategies to support scale-up of TPT in high-prevalence settings, where the potential benefit for affected individuals is considerable and emphasise that patients must be at the centre of TPT policies. Addressing health system requirements for scale-up will be important to ensure that programs can deliver treatment safely, efficiently and sustainably.

Nachegea et al. (2021a) discuss the negative impact of COVID-19 on TB and HIV health services. They suggest approaches to mitigate the growing burden of these colliding epidemics in sub-Saharan Africa, which bear the highest proportions of TB and HIV cases worldwide. The COVID-19 pandemic has added an additional burden to already overstretched health systems, which, among many other things, were struggling to deal with the longstanding dual epidemics of TB and HIV.

Knipper et al. (2021) review the COVID-19 pandemic threat to derailing health services for forcibly displaced people and migrant populations, populations who face specific vulnerabilities placing them at increased risk of developing TB if they have LTBI, or not being diagnosed as having active TB. Highlighting three case studies as examples—from Peru, South Africa, and Syria—they

illustrate the lived experience of forced migration and mobile populations, and the impact of COVID-19 on TB among these populations. They indicate that addressing TB, COVID-19 and migration from a syndemic perspective, not only draws systematic attention to comorbidity and the relevance of social and structural context, but also helps to find solutions. The true reality of syndemic interactions can only be fully understood by considering a particular population and bio-social context and ensuring that they receive the comprehensive care that they need. It also provides avenues for strengthening and expanding the existing infrastructure for TB care to tackle both COVID-19 and TB in migrants and refugees in an integrated and synergistic manner.

Over a quarter of the individuals diagnosed with TB in the European Union region are born outside the EU and the proportion has been increasing steadily. Over 50% of TB cases in Italy are foreign born migrants. [Goscé et al. \(2021\)](#) describe the EDETECT-TB project in Italy which implemented and evaluated active TB screening in the migrant population and their study confirmed that early case detection is a cost-effective intervention and that targeted post-arrival early screening ensures that potential further transmission is averted.

Recurrent pulmonary TB is a growing, important and neglected problem affecting treated TB patients and TB health services across the world, particularly in sub-Saharan Africa and Asia. Analyses and identification of differences in clinical features between recurrent PTB and newly diagnosed PTB may lead to improved management recommendations. [Nagu et al. \(2021\)](#) performed a prospective case-controlled study of clinical and imaging features of patients with recurrent pulmonary TB (RPTB) and compared them with those of newly diagnosed PTB cases. They found that hemoptysis, lung parenchymal damage, and patients being older than 45 years of age are significant features of RPTB, suggesting that management of TB cases should focus on risk factors for recurrence, and design a more holistic model of care to prevent long term lung injury.

[Kizny Gordon et al. \(2021\)](#) review the clinical and public health utility benefits of *M. tuberculosis* whole genome sequencing (WGS), including provision of more rapid and complete information on drug-resistance, detection of transmission clusters, contamination events, mixed infections, and to differentiate between re-infection and relapse. They also discuss future advances that have the potential to change the landscape of TB diagnostics and management, such as culture-free sequencing and surveillance of antimicrobial resistance to guide precision medicine approaches, as well as some of the challenges involved. Whole genome sequencing-based differentiation between re-infection and relapse in TB cases has important implications for public health, especially in patients with human immunodeficiency virus (HIV) coinfection. [Shanmugam et al. \(2021\)](#) compared Mycobacterial Interspersed Repeat Unit (MIRU) typing and spoligotyping with WGS to differentiate between relapse and re-infection and assessed the value of WGS to track acquired drug resistance in those with relapse after successful treatment. Comparing *M. tuberculosis* genomes, they found that 95% of TB recurrences in the HIV-negative cohort were due to relapse, while the majority of TB recurrences in the HIV-positive cohort were due to re-infection, highlighting the need for effective infection control in HIV care setting.

WGS for *M. tuberculosis* drug resistance detection is now available in diagnostic and reference laboratories worldwide. Characterizing novel mutations and deletions associated with drug resistant *M. tuberculosis* could ultimately lead to better treatment outcomes. The additional value WGS provides in inferring drug resistance is discussed by [Lam et al. \(2021\)](#). They sequenced genomes from all *M. tuberculosis* isolates in NSW, Australia, collected between 2016 and 2019 and tracked the prevalence of

drug resistance and circulation of predominant *M. tuberculosis* lineages. They demonstrated that WGS was able to capture an additional 20% of drug resistance mutations not detected by commercial diagnostic assays, signaling the additional value that WGS offers over existing genotypic drug resistance assays in terms of sensitivity.

The Bandim TBscore is a clinical score that predicts treatment outcome in TB patients and may prove useful as an indicator of which healthcare-seeking adults to refer for sputum smear microscopy. [Rudolf et al. \(2021\)](#) conducted a stepped wedge cluster-randomized trial at six health centers in Bissau, Guinea-Bissau, and Gondar, Ethiopia. They conclude that it is an implementable approach and solution to an old and yet unresolved challenge. Using the TBscore for triage before smear microscopy may improve case detection and decrease mortality if there is sufficient laboratory capacity to increase sputum smears.

[Marais et al. \(2021\)](#) discuss new advances to close persistent gaps in the prevention and diagnosis of childhood TB. Almost all children estimated in the Global TB Report 2020 to have died from TB were never diagnosed or offered TB treatment. Thus new approaches are required to ensure that effective TB prevention strategies are implemented and to improve the accuracy of current and new diagnostic (rule-in and rule-out) tests. Reducing the major gaps in TB preventive treatment (TPT) will require strong political commitment and concerted effort, with major upscaling of household contact investigation. While widespread roll-out of Xpert MTB/RIF Ultra[®] should be supported and could improve case detection in young children, they caution that specimen collection remains difficult and test sensitivity low. The use of non-sputum specimens are essential to improve diagnostic access, but given the limited accuracy of all available tests and the excellent tolerance of TB drugs in children the global community may have to accept some over-treatment using the most feasible approaches available; if we are serious about closing the persistent case detection gap in young children.

Zoonotic TB is evolving in an everchanging global landscape. Despite slow reductions in the annual burden of active TB cases, Zoonotic TB (zTB) remains a poorly monitored and poorly addressed global burden. [Kock et al. \(2021\)](#) in their zoonotic TB review highlight the higher incidence in some specific regions and countries, especially where close association exists between growing numbers of cattle (the major source of *Mycobacterium bovis* (*M. bovis*) and people, many suffering from poverty and where milk or dairy products are consumed un-pasteurized. Attention needs to be re-focused to prevent a rapid increase in zTB disease along with growing intensification of dairy production. Evidence of new zoonotic mycobacterial strains such as *M. orygis*, especially in South Asia and Africa warrants rapid assessment of drivers and risk, and the development of appropriate interventions. Control of *M. bovis* in cattle through early detection of infection and disease, as well as pasteurization of dairy products, remains the mainstay of reducing zTB risk to humans, while new point of care diagnostics will help to detect and appropriately treat human cases.

[Lipman et al. \(2021\)](#) highlight that pulmonary disease caused by non-tuberculous mycobacteria (NTM) is often missed, is difficult to treat successfully in an often frail population with other chronic conditions such as bronchiectasis and COPD, is on the rise globally, and results in significant morbidity and even mortality. They identify and discuss key issues in NTM management. In addition to the need for research into epidemiology, immunology and treatment, they recommend an 8-point plan including greater use of patient and clinician networks to educate primary and secondary care clinicians and promote a multidisciplinary team approach with shared patient-clinician decision making throughout care. They also call for co-ordinated patient-

focused research to improve what is often a limited evidence base to guide management.

Nachega et al. (2021b) re-ignite the century old controversies on the Bacille Calmette–Guérin (BCG) vaccine, which is yet again a focus of global attention—this time due to the global COVID-19 pandemic caused by SARS-CoV-2. Their viewpoint focusses on the assumptions, knowns, unknowns and need for developing an accurate scientific evidence base for suggestions of potential cross-protection against SARS-CoV-2 infection. Recent studies have shown that human CD4+ and CD8+ T-cells primed with a BCG-derived peptide developed high reactivity to its corresponding SARS-CoV-2-derived peptide. Furthermore, BCG vaccine has been shown to substantially increase interferon-gamma (IFN- γ) production and its effects on CD4+ T-cells and these nonspecific immune responses could be harnessed as cross protection against severe forms of COVID-19. They highlight that there are numerous clinical trials in progress to determine the effectiveness of BCG vaccination for prevention of SARS-CoV-2 infection or to reduce morbidity and mortality associated with COVID-19. Data from ongoing BCG trials may shed light on the mechanisms underlying BCG-mediated immunity and could lead to improved efficacy, increased tolerance of treatment, and identification of benefits combining BCG and COVID-19 vaccines, or other adjunct immunotherapies.

There are several ongoing studies which are defining the interactions between COVID-19 and TB. Petrone et al. (2021) evaluated IFN- γ levels in whole blood after stimulation with *Mtb* antigens in the Quantiferon-Plus format or with peptides derived from SARS-CoV-2 spike protein, Wuhan-Hu-1 isolate (CD4-S). They demonstrated for the first time that COVID-19 patients, either with TB or LTBI, have a low ability to build an immune response to SARS-CoV-2 while retaining the ability to respond to *Mtb*-specific antigens. These results may have important implications for the clinical management of COVID-19 individuals coinfecting with *Mtb*.

Fatima et al. (2021) focus on TB control in Pakistan and discuss the importance of a multi-pronged approach for building better TB control systems to cope with the effects of COVID-19. As in all high-TB endemic countries, COVID-19 is impacting negatively in Pakistan. The COVID-19 has provided an opportunity in country to introduce some adaptations to bring TB care closer to communities, increased investments in human resources and addressing stigma, and implementation of telemedicine systems for follow-up and consultations. Global health inequities driving TB epidemiology, including the environment and climate control, gender, age, socio-economic status, and wealth as well as resource distribution, need to be addressed by multiple approaches and sectors.

The WHO 2020 global TB Report estimates that in 2019 there were an estimated 500,000 cases of multi-drug resistant TB (MDR-TB) of which only 186,772 MDR-TB cases were diagnosed, and positive treatment outcomes were achieved in 57% of them. These data highlight the need for accelerating and improving MDR-TB screening, diagnostic, treatment and patient follow-up services. Maretbayeva et al. (2021) present the first study from Kazakhstan on culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of MDR-TB.

Tiberi et al. (2021) emphasize that the direct and indirect negative impacts of COVID-19 on health services overall, including national TB programs and TB services add further to longstanding challenges for tackling MDR-TB such as availability of budgets, rollout of TB diagnostics and TB drugs. Implementation of latest WHO guidelines for MDR-TB, in light of COVID-19 disruption of TB services will be difficult and, it is anticipated the numbers of MDR-TB cases will rise in 2021 and 2022 and will affect MDR-TB treatment outcomes further. Investing more in development of

new TB drugs and shorter MDR-TB treatment regimens is required in anticipation of emerging drug resistance to new TB drug regimens. These include closely aligning and optimizing COVID-19 and MDR-TB algorithms and improving clinical capacity to offer rapid diagnosis, quality treatment and follow up, and ensuring availability of quality, regular supply of cost-free TB drugs (for both DS-TB and MDR-TB) through improved procurement and distribution of TB drugs.

Sahu et al. (2021) remind us that it has been over two years since global leaders signed the UN General Assembly high level meeting on TB (UNGA-HLM-TB) declaration which committed to mobilize 15 billion USD per annum for TB, 13 billion USD for TB care and 2 billion USD per annum for TB R&D (UNGA, 2018). They point out that the follow up October 21, 2020 UN Secretary-General report (UNGA, 2020) on progress towards implementation of the UNHLM political declaration on TB stresses that although high-level commitments and targets had galvanized global and national progress towards ending TB, urgent and more ambitious investments and actions were required, especially in lieu of the COVID-19 pandemic where associated public health measures and travel restrictions, have disrupted health services universally. The report sets out 10 priority recommendations to get the world on track to reach agreed targets by 2022. Importantly, all countries should sign up to these ten priority recommendations and the Global Fund needs to increase its current commitment to mitigating the impact of COVID-19 on TB services (Global Fund, 2020). Additional supplementary measures and resources are required to reduce the accumulating pool of undetected people with TB. These should include ramped-up active case-finding with intensive community engagement and contact tracing to sustain awareness of recognizing and responding to symptoms suggestive of TB, using digital technology and other diagnostic tools, and an uninterrupted supply of quality TB drugs and care for all people with TB (Stop TB Partnership, 2020).

On World TB Day 2021, every political and community leader, and funding agency must get the message that it is time to reduce global inequities as we work towards a TB free world. While there is a continued need to develop new prevention and treatment tools for TB, obtaining the resources required for implementation of current TB diagnostic and management tools could significantly advance TB control efforts. World leaders need to urgently address and reverse the socio-economic and health services impact of the COVID-19 pandemic. As COVID-19 vaccines and public health measures start to have an effect on slowing down the COVID-19 outbreak, every effort must be made by to ensure that health services and prevention programs for TB are not compromised. The commitment of western governments to the rapid development and rollout of COVID-19 vaccines is commendable, but it is important to ensure that no-one is 'left behind'. It's now time for them to invest with equal commitment to ending the TB epidemic. Reality showed us that it can be achieved, if there is serious political will which is translated into measurable, tangible actions resulting in impactful deliverables.

Conflicts of interest

All authors have a specific interest in Tuberculosis and have contributed to articles in this special IJID issue for World TB Day 2021. All authors declare no other conflicts of interest

Acknowledgements

Professors Zumla, Kock and Abubakar, and Drs Kapata and Haider, are members of the European and Developing Countries Clinical Trials Partnership project Pan-African Network on

Emerging and Re-Emerging Infections (PANDORA-ID-NET, Grant Agreement RIA2016E-1609, (<https://www.pandora-id.net/>)). Sir Prof Zumla is in receipt of a UK-National Institutes of Health Research senior investigator award and is a 2020 Mahathir Science Award Laureate. Professor Nachega is supported by the NIH/Fogarty International Center (FIC) grant numbers 1R25TW011217-01 (African Association for Health Professions Education and Research); 1D43TW010937-01A1 (the University of Pittsburgh HIV-Comorbidities Research Training Program in South Africa–Pitt-HRTP-SA); and 1R21TW011706-01. Prof Maeurer is a member of the innate immunity advisory group of the BMGF.

Transparency declaration

This article is part of a supplement entitled Commemorating World Tuberculosis Day March 24th, 2021: “The Clock is Ticking” published with support from an unrestricted educational grant from QIAGEN Sciences Inc.

References

- Chakaya J, Khan M, Ntoumi F, Akillu E, Fatima R, Mwaba P, et al. Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts. *Int J Infect Dis* 2021;113(S1):S7–S12 .
- Cilloni L, Fu H, Vesga JF, Dowdy D, Pretorius C, Ahmedov S, et al. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. *EclinicalMedicine* 2020;28(October):100603, doi:<http://dx.doi.org/10.1016/j.eclinm.2020.100603>.
- Fatima R, Akhtar N, Yaqoob A, Harries AD, Khan MS. Building better tuberculosis control systems in a post-COVID world: learning from Pakistan during the COVID-19 pandemic. *Int J Infect Dis* 2021;113(S1):S88–S90 .
- Fox GJ, Nguyen TA, Coleman M, Trajman A, Velen K, Marais BJ. Mycobacterium tuberculosis; latent tuberculosis; preventive therapy; prophylaxis; patient-centered care. *Int J Infect Dis* 2021;113(S1):S13–S15 .
- Global Fund to Fight AIDS, Tuberculosis and malaria. 2020 COVID-19 Information Note: “Catch-up” Plans to Mitigate the Impact of COVID-19 on Tuberculosis Services. https://www.theglobalfund.org/media/10232/covid19_tuberculosis-servicesimpact_guidancenote_en.pdf [Accessed 7 February 2021].
- Goscé L, Girardi E, Allel K, Cirillo DM, Barcellini L, Stancanelli G, et al. Tackling TB in migrants arriving at Europe’s southern border. *Int J Infect Dis* 2021;113(S1):S28–S32 .
- Kizny Gordon A, Marais B, Walker TM, Sintchenko V. Clinical and public health utility of Mycobacterium tuberculosis whole genome sequencing. *Int J Infect Dis* 2021;113(S1):S40–S42 .
- Knipper M, Sedas AC, Keshavjee S, Abbara A, Almhawish N, Alashawi H, et al. The need for protecting and enhancing TB health policies and services for forcibly displaced and migrant populations during the ongoing COVID-19 pandemic. *Int J Infect Dis* 2021;113(S1):S22–S27 .
- Kock R, Michel AL, Yeboah-Manu D, Azhar EI, Torrelles JB, SI, et al. Zoonotic tuberculosis – the changing landscape. *Int J Infect Dis* 2021;113(S1):S68–S72 .
- Lam C, Martinez E, Crighton T, Furlong C, Donnan E, Marais BJ, et al. Value of routine whole genome sequencing for Mycobacterium tuberculosis drug resistance detection. *Int J Infect Dis* 2021;113(S1):S48–S54 .
- Lipman M, Kunst H, Loebinger MR, Milburn HJ, King M. Non tuberculous mycobacteria pulmonary disease: patients and clinicians working together to improve the evidence base for care. *Int J Infect Dis* 2021;113(S1):S73–7 .
- Marais BJ, Verkuil S, Casenghi M, Triasih R, Hesselting AC, Mandalakas AM, et al. Paediatric tuberculosis – new advances to close persistent gaps. *Int J Infect Dis* 2021;113(S1):S63–7 .
- Maretbayeva SM, Rakisheva AS, Adenov MM, Yeraliyeva LT, Algozhin YZ, Stambekova AT, et al. Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis in Kazakhstan. *Int J Infect Dis* 2021;113(S1):S91–S95 .
- Nachega JB, Kapata N, Sam-Agudu NA, Decloedt EH, Katoto PDMC, Nagu T, et al. Minimizing the impact of the triple burden of COVID-19, tuberculosis and HIV on health services in sub-Saharan Africa. *Int J Infect Dis* 2021a;113(S1):S16–21 .
- Nachega JB, Maeurer M, Sam-Agudu NA, Chakaya J, Katoto PDM, Zumla A. Bacille Calmette-Guérin (BCG) vaccine and potential cross-protection against SARS-CoV-2 infection – Assumptions, knowns, unknowns and need for developing an accurate scientific evidence base. *Int J Infect Dis* 2021b;113(S1):S78–81 .
- Nagu TJ, Mboka MA, Nkrumbih ZF, Shayo G, Mizinduko MM, Komba EV, et al. Clinical and imaging features of adults with recurrent pulmonary tuberculosis – a prospective case-controlled study. *Int J Infect Dis* 2021;113(S1):S33–S39 .
- Petrone L, Petruccioli E, Vanini V, Cuzzi G, Gualano G, Vittozzi P, et al. Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2. *Int J Infect Dis* 2021;113(S1):S82–7 .
- Rudolf F, Abate E, Moges B, Mendes AM, Mengistu MY, Sifna A, et al. Increasing smear positive tuberculosis detection using a clinical score – A stepped wedge multicenter trial from Africa. *Int J Infect Dis* 2021;113(S1):S55–S62 .
- Sahu S, Ditiu L, Lawson L, Ntoumi F, Arakaki D, Zumla A. UN General Assembly tuberculosis targets: are we on track? *Lancet* 2020;395(10228):928–30 .
- Sahu S, Ditiu L, Sachdeva KS, Zumla A. Recovering from the impact of the Covid-19 pandemic and accelerating to achieving the United Nations General Assembly tuberculosis targets. *Int J Infect Dis* 2021;113(S1):S100–3 .
- Shanmugam S, Bachmann NL, Martinez E, Menon R, Narendran G, Narendran S, et al. Whole genome sequencing based differentiation between re-infection and relapse in Indian patients with tuberculosis recurrence, with and without HIV co-infection. *Int J Infect Dis* 2021;113(S1):S43–S47 .
- Stop TB Partnership. A deadly divide: TB commitments vs TB realities: a communities report on progress towards the UN political declaration on the fight against TB and a call to action to close the gaps in TB targets. 2020. . [Accessed 20 February 2021] http://www.stoptb.org/assets/documents/communities/The%20Deadly%20Divide_TB%20Commitments%20vs%20TB%20Realities%20FINAL%20HLM%20Report.pdf.
- Tiberi S, Vjecha MJ, Zumla A, Galvin J, Migliori GB, Zumla A. Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic. *Int J Infect Dis* 2021;113(S1):S96–9 .
- UNGA. United Nations General Assembly resolution A/RES/73/3; October 2018. Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis. 2018. . [Accessed 20 February 2021] https://www.un.org/en/ga/search/view_doc.asp?symbol=A/RES/73/3.
- UNGA. UN General Assembly 75th session September 2020. Progress towards the achievement of global tuberculosis targets and implementation of the political declaration of the high level meeting of the General Assembly on the fight against tuberculosis: Report of the Secretary-General. 2020. . [Accessed 3 February 2021] <https://undocs.org/en/A/75/236>.
- Wallstedt H, Maeurer M. The history of tuberculosis management in Sweden. *Int J Infect Dis* 2015;32:179–82 .
- WHO. Global tuberculosis report 2020. World Health Organization; 2021. . [Accessed 7 February 2021] <https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf>.
- WHO. World Tuberculosis Day 2021 The Clock is Ticking. 2021. . [Accessed 20 February 2021] <https://www.who.int/campaigns/world-tb-day/world-tb-day-2021>.
- WHO. COVID-19 dashboard. 2021. . [Accessed 15 March 2021] <https://covid19.who.int/>.

Alimuiddin Zumla

Department of Infection, Division of Infection and Immunity,
University College London, and NIHR Biomedical Research Centre,
University College London Hospitals NHS Foundation Trust, London,
United Kingdom

Jeremiah Chakaya^{a,b}

^aDepartment of Medicine, Therapeutics and Dermatology, Kenyatta
University, Nairobi, Kenya

^bDepartment of Clinical Sciences, Liverpool School of Tropical
Medicine, Liverpool, United Kingdom

Mishal Khan

Faculty of Public Health and Policy, London School of Hygiene and
Tropical Medicine, London, United Kingdom

Razia Fatima

National TB Control Program, Islamabad, Common Unit (HIV, TB,
Malaria), Chak Shahzad, Islamabad, Pakistan

Christian Wejse

Department of Infectious Diseases, Aarhus University Hospital,
Skejby, Denmark

Seif Al-Abri

Directorate General for Disease Surveillance and Control, Ministry of
Health, Oman

Greg J. Fox

WHO Collaborating Centre for Tuberculosis, Faculty of Medicine and
Health, The University of Sydney, New South Wales, Australia

Jean Nachega^{a,b,c}

^aDepartment of Medicine and Center for Infectious Diseases,
Stellenbosch University Faculty of Medicine and Health Sciences, Cape
Town, South Africa

^bUniversity of Pittsburgh, Pittsburgh, PA, USA

^cUniversity of Stellenbosch, South Africa

Nathan Kapata
Ministry of Health, Zambia National Public Health Institute, Lusaka,
Zambia

Michael Knipper
Institute for the History of Medicine, University Justus Liebig Giessen,
Germany

Miriam Orcutt
Institute for Global Health, University College London, United
Kingdom

Lara Goscé
University College London, United Kingdom

Ibrahim Abubakar
Institute for Global Health, University College London, United
Kingdom

Tumaini Joseph Nagu
Muhimbili University of Health and Allied Sciences Dar es Salaam, Dar
es Salaam, Tanzania

Ferdinand Mugusi
Muhimbili University of Health and Allied Sciences, Dar es Salaam,
Tanzania

Alice Kizny Gordon
Centre for Infectious Diseases and Microbiology (CIDM), Institute of
Clinical Pathology and Medical Research (ICPMR), The University of
Sydney, New South Wales, Australia

Sivakumar Shanmugam
National Institute for Research in Tuberculosis, Chennai, Tamil Nadu,
India

Nathan Lloyd Bachmann
Centre for Infectious Diseases and Microbiology (CIDM), University of
Sydney, New South Wales, Australia

Connie Lam
Institute of Clinical Pathology and Medical Research (ICPMR),
Westmead, New South Wales, Australia

Vitali Sintchenko
WHO Collaborating Centre for Tuberculosis, Marie Bashir Institute for
Infectious Diseases and Biosecurity and Centre for Infectious Diseases
and Microbiology (CIDM), University of Sydney, New South Wales,
Australia

Frauke Rudolf^{a,b}
^aDepartment of Infectious Diseases, Aarhus University Hospital,
Skejby, Denmark

^bBandim Health Project, INDEPTH Network, Apartado 861, Bissau,
Guinea-Bissau

Farhana Amanullah
Department of Pediatrics, The Indus Hospital, Karachi, Pakistan

Richard Kock
Royal Veterinary College, Hatfield, United Kingdom

Najmul Haider
Pathobiology and Population Sciences, The Royal Veterinary College,
Hawkshead Campus, Hatfield, United Kingdom

Marc Lipman
Respiratory Medicine, Royal Free London NHS Foundation Trust, UCL
Respiratory Medicine, University College London, London, United
Kingdom

Michael King
NTM Patient Care UK, The Grove Centre London, United Kingdom

Markus Maeurer^{a,b}
^aChampalimaud Centre for the Unknown, Lisbon, Portugal

^bUniversity of Mainz, Mainz, Germany

Delia Goletti
Linda Petrone
Translational Research Unit, National Institute for Infectious Diseases
“Lazzaro Spallanzani”- IRCCS, Rome, Italy

Aashifa Yaqoob
Common Management Unit (TB, HIV & Malaria), Islamabad, Pakistan

Simon Tiberi
Blizard Institute, Barts and The London School of Medicine and
Dentistry, Queen Mary University of London, Division of Infection,
Royal London Hospital, Barts Health NHS Trust, London, United
Kingdom

Lucica Ditiu
Suvanand Sahu
Stop TB Partnership, Geneva, Switzerland

Ben Marais
WHO Collaborating Centre for Tuberculosis and the Marie Bashir
Institute for Infectious Diseases and Biosecurity, The University of
Sydney, New South Wales, Australia

Assiya Marat Issayeva
Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan

Eskild Petersen^{a,b,c,*}
^aInstitute for Clinical Medicine, Faculty of Health Science, University
of Aarhus, Denmark

^bEuropean Society for Clinical Microbiology and Infectious Diseases,
ESCMID, Basel, Switzerland

^cInternational Society for Infectious Diseases, ISID, Boston, USA

* Corresponding author at: Institute for Clinical Medicine, Faculty
of Health Science, University of Aarhus, Denmark.
E-mail addresses: a.zumla@ucl.ac.uk (A. Zumla),
chakaya.jm@gmail.com (J. Chakaya),
Mishal.Khan@lshtm.ac.uk (M. Khan),
drraziafatima@gmail.com (R. Fatima),
wejse@ph.au.dk (C. Wejse),
salabri@gmail.com (S. Al-Abri),
greg.fox@sydney.edu.au (G. Fox),
JBN16@PITT.EDU (J. Nachega),
nkapata@gmail.com (N. Kapata),
Michael.Knipper@histor.med.uni-giessen.de (M. Knipper),
m.orcutt@ucl.ac.uk (M. Orcutt),
l.gosce@ucl.ac.uk (L. Goscé),
i.abubakar@ucl.ac.uk (I. Abubakar),
jtjoyce20@gmail.com (T. Nagu),
fm.mugusi@gmail.com (F. Mugusi),
alice_kg@hotmail.com (A. Gordon),
shanmugamsiva@nirt.res.in (S. Shanmugam),
nathan.bachmann@sydney.edu.au (N. Bachmann),
connie.lam@health.nsw.gov.au (C. Lam),
vitali.sintchenko@health.nsw.gov.au (V. Sintchenko),
frauke.rudolf@clin.au.dk (F. Rudolf),
farhana.amanullah@tih.org.pk (F. Amanullah),
rkock@rvc.ac.uk (R. Kock),
nhaider@rvc.ac.uk (N. Haider),
marclipman@nhs.net (M. Lipman),

michael.king@ucl.ac.uk (M. King),
markus.maeurer@fundacaochampalimaud.pt (M. Maeurer),
delia.goletti@inmi.it (D. Goletti),
linda.petrone@inmi.it (L. Petrone),
aashifa.yaqoob@gmail.com (A. Yaqoob),
simon.tiberi@nhs.net (S. Tiberi),

lucicad@stoptb.org (L. Ditiu),
sahus@stoptb.org (S. Sahu),
ben.marais@health.nsw.gov.au (B. Marais),
issayeva17@mail.ru (A. Issayeva),
eskild.petersen@gmail.com (E. Petersen).